Received: from TEHIK-EX02.sotsiaalministeerium.ee (10.11.26.102) by TEHIK-EX02.sotsiaalministeerium.ee (10.11.26.102) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_128_GCM_SHA256) id 15.1.2507.61 via Mailbox Transport; Mon, 16 Mar 2026 17:16:32 +0200 Received: from TEHIK-EX02.sotsiaalministeerium.ee (10.11.26.102) by TEHIK-EX02.sotsiaalministeerium.ee (10.11.26.102) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_128_GCM_SHA256) id 15.1.2507.61; Mon, 16 Mar 2026 17:16:32 +0200 Received: from TEHIK-EX02.sotsiaalministeerium.ee ([fe80::10a6:c241:8672:ab6b]) by TEHIK-EX02.sotsiaalministeerium.ee ([fe80::10a6:c241:8672:ab6b%4]) with mapi id 15.01.2507.061; Mon, 16 Mar 2026 17:16:32 +0200 From: "Kairi Laius" To: =?utf-8?Q?Anna_L=C3=B6fdahl?= Cc: =?utf-8?Q?K=C3=A4rolin_Jenas?= References: In-Reply-To: Subject: Vs: Taotlus Eesti Ravimiametile Date: Mon, 16 Mar 2026 18:16:32 +0300 Message-ID: <35bd0e9b656d4001affb6b8d9f01e3a9@ravimiamet.ee> MIME-Version: 1.0 Content-Type: multipart/related; boundary="----=_NextPart_000_00B1_01DCD106.238303F0" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQJe0qGpZM9Sy5/g6a9AoDqBvg4ZjwIqnmjRAtVP60gCQiXNWAHmoETAAdp7MgwB6TkdlQ== X-MS-Has-Attach: yes X-MS-TNEF-Correlator: <35bd0e9b656d4001affb6b8d9f01e3a9@ravimiamet.ee> X-MS-Exchange-Organization-Network-Message-Id: 1913a7a5-839e-48fc-80e5-08de836f0172 X-MS-Exchange-Organization-AVStamp-Enterprise: 1.0 X-MS-Exchange-Organization-AuthSource: TEHIK-EX02.sotsiaalministeerium.ee X-MS-Exchange-Organization-AuthAs: Internal X-MS-Exchange-Transport-EndToEndLatency: 00:00:00.2881076 X-MS-Exchange-Processed-By-BccFoldering: 15.01.2507.060 Content-Language: en-us acceptlanguage: et-EE, en-US x-ms-exchange-organization-originalclientipaddress: 10.53.0.194 x-ms-exchange-organization-originalserveripaddress: 10.11.26.102 X-OlkEid: 00000000DE49643447CB3F4AABE624F9EDADF372070034AD76187591974DBF6C4F76951C873A0100020000000000837E3DDB5EA6EE48A9C5823F3E555C1A000000001B960000EEBDB17325049846B0403601D761C2DB X-MS-Exchange-Organization-SCL: -1 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-Exchange-Organization-AuthMechanism: 04 X-Originating-IP: [10.53.0.194] This is a multipart message in MIME format. ------=_NextPart_000_00B1_01DCD106.238303F0 Content-Type: multipart/alternative; boundary="----=_NextPart_001_00B2_01DCD106.238303F0" ------=_NextPart_001_00B2_01DCD106.238303F0 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit Saatja: Anna Löfdahl > Saatmisaeg: esmaspäev, 2. märts 2026 12:05 Adressaat: Kairi Laius > Teema: Taotlus Eesti Ravimiametile Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. TAOTLUS EESTI RAVIMIAMETILE Pöördun Teie poole küsimusega seotud Informatsioonivabaduse Aktiga ning küsida, kas oleks võimalik saada ravimite otsuse ootel olevate taotluste arvu (nii detsentraliseeritud kui ka tsentraliseeritud müügiloaprotseduurid), mis antud hetkel ootavad otsust Eesti Ravimiametis. Sarnasel viisil avaldab Euroopa Meditsiiniagentuur tsentraliseeritud müügiloaprotseduure, mis on osa ravimitega seotud tehingute läbipaistvuse initsiatiivist Euroopas (rohkem infot: Medicines for human use under evaluation | European Medicines Agency (EMA) Sooviksin küsida, kas alloleva toimeainega on hetkel müügiloataotlusi ootel ning mitu müügiloa taotlust hetkel ootab otsust: * Trifluridine/Tipiracil (ATC: L01BC59) * Semaglutide (ATC: A10BJ06) * Ivacaftor (ATC: R07AX02) * Indacaterol+Glycopyrronium (ATC: R03AL04) Antud päring on seotud ainult ootel olevate müügiloataotlustega ning taotluste arvuga. Päring ei hõlma endas lisainformatsiooni. Olen meeleldi nõus vastama täiendavatele küsimustele kui Teil peaks neid tekkima. Vastust ootama jäädes ja ettetänades. Lugupidamisega, AnnaLöfdahl PhD (Med.) Mobile: +45 31 14 16 74 E‑mail: ald@tpr-group.com Amaliegade 13, 2 ​1256 København K ​Denmark www.tpr-group.com This mail (including attachments) is confidential and may be legally privileged. If you have received it in error please notify the sender by returning the e-mail and remove it from your system. Any unauthorized use or dissemination of this message in whole or in part is strictly prohibited. Please note that e-mails are susceptible to change. TPR-Group shall not be liable for unauthorized use of the information contained in this communication ------=_NextPart_001_00B2_01DCD106.238303F0 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable

 

Saatja: Anna L=C3=B6fdahl <ald@tpr-group.com> =
Saatmisaeg: esmasp=C3=A4ev, 2. m=C3=A4rts 2026 = 12:05
Adressaat: Kairi Laius <Kairi.Laius@ravimiamet.ee&g= t;
Teema: Taotlus Eesti = Ravimiametile

 

T=C3=A4helepanu! Tegemist on = v=C3=A4ljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral = palume linke ja faile mitte avada.


 

TAOTLUS EESTI = RAVIMIAMETILE

P=C3=B6=C3=B6rdun Teie = poole k=C3=BCsimusega seotud Informatsioonivabaduse Aktiga ning = k=C3=BCsida, kas oleks v=C3=B5imalik saada ravimite otsuse ootel olevate = taotluste arvu (nii detsentraliseeritud kui ka tsentraliseeritud = m=C3=BC=C3=BCgiloaprotseduurid), mis antud hetkel ootavad otsust Eesti = Ravimiametis. Sarnasel viisil avaldab Euroopa Meditsiiniagentuur = tsentraliseeritud m=C3=BC=C3=BCgiloaprotseduure, mis on osa ravimitega = seotud tehingute l=C3=A4bipaistvuse initsiatiivist Euroopas (rohkem = infot: Medicines for human use under evaluation | European = Medicines Agency (EMA)

 

Sooviksin k=C3=BCsida, kas alloleva = toimeainega on hetkel m=C3=BC=C3=BCgiloataotlusi ootel ning mitu = m=C3=BC=C3=BCgiloa taotlust hetkel ootab otsust:

 

  • Trifluridine/Tipiracil (ATC: = L01BC59)
  • Semaglutide (ATC: = A10BJ06)
  • Ivacaftor (ATC: = R07AX02)
  • Indacaterol+Glycopyrronium (ATC: = R03AL04)

 

Antud p=C3=A4ring on seotud ainult = ootel olevate m=C3=BC=C3=BCgiloataotlustega ning taotluste arvuga. = P=C3=A4ring ei h=C3=B5lma endas = lisainformatsiooni. 

 

Olen meeleldi n=C3=B5us vastama = t=C3=A4iendavatele k=C3=BCsimustele kui Teil peaks neid = tekkima.

 

Vastust = ootama j=C3=A4=C3=A4des ja ettet=C3=A4nades.

 

Lugupidamisega,

 

Anna=E2= =80=8B=E2=80=8B=E2=80=8B= =E2=80= =8B 

L=C3=B6fdahl

PhD (Med.)

Mobile: +45 31 14 16&nbs= p;74

E=E2=80=91mail: ald@tpr-group.com

 

Amaliegade 13, 2
=E2=80=8B1256 K=C3=B8benhavn K=E2=80=8BDenmark

 

www.tpr-group.com

3Dlogo

= This mail (including attachments) is confidential and may be legally = privileged. If you have received it in error please notify the sender by = returning the e-mail and remove it from your system. Any unauthorized = use or dissemination of this message in whole or in part is strictly = prohibited. Please note that e-mails are susceptible to change. = TPR-Group shall not be liable for unauthorized use of the information = contained in this = communication

 

------=_NextPart_001_00B2_01DCD106.238303F0-- ------=_NextPart_000_00B1_01DCD106.238303F0 Content-Type: image/png; name="image001.png" Content-Transfer-Encoding: base64 Content-ID: iVBORw0KGgoAAAANSUhEUgAAAdUAAAAzCAYAAADB05LcAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJ bWFnZVJlYWR5ccllPAAAA/RpVFh0WE1MOmNvbS5hZG9iZS54bXAAAAAAADw/eHBhY2tldCBiZWdp bj0i77u/IiBpZD0iVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkIj8+IDx4OnhtcG1ldGEgeG1sbnM6 eD0iYWRvYmU6bnM6bWV0YS8iIHg6eG1wdGs9IkFkb2JlIFhNUCBDb3JlIDUuMC1jMDYxIDY0LjE0 MDk0OSwgMjAxMC8xMi8wNy0xMDo1NzowMSAgICAgICAgIj4gPHJkZjpSREYgeG1sbnM6cmRmPSJo dHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj4gPHJkZjpEZXNjcmlw dGlvbiByZGY6YWJvdXQ9IiIgeG1sbnM6eG1wTU09Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEu MC9tbS8iIHhtbG5zOnN0UmVmPSJodHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvc1R5cGUvUmVz b3VyY2VSZWYjIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iIHhtbG5z OmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyIgeG1wTU06T3JpZ2luYWxEb2N1 bWVudElEPSJ1dWlkOjVEMjA4OTI0OTNCRkRCMTE5MTRBODU5MEQzMTUwOEM4IiB4bXBNTTpEb2N1 bWVudElEPSJ4bXAuZGlkOjk5MkJERjM0MUVBMTExRUNCNjk3RjUwMzZBMEY5NDQzIiB4bXBNTTpJ bnN0YW5jZUlEPSJ4bXAuaWlkOjk5MkJERjMzMUVBMTExRUNCNjk3RjUwMzZBMEY5NDQzIiB4bXA6 Q3JlYXRvclRvb2w9IkFkb2JlIElsbHVzdHJhdG9yIENTNS4xIj4gPHhtcE1NOkRlcml2ZWRGcm9t IHN0UmVmOmluc3RhbmNlSUQ9InhtcC5paWQ6Rjk3RjExNzQwNzIwNjgxMTgwODNDMkJCRUQwRjVB RjIiIHN0UmVmOmRvY3VtZW50SUQ9InhtcC5kaWQ6Rjk3RjExNzQwNzIwNjgxMTgwODNDMkJCRUQw RjVBRjIiLz4gPGRjOnRpdGxlPiA8cmRmOkFsdD4gPHJkZjpsaSB4bWw6bGFuZz0ieC1kZWZhdWx0 Ij50cHJnLWxvZ28tY29sb3ItcG9zaXRpdmU8L3JkZjpsaT4gPC9yZGY6QWx0PiA8L2RjOnRpdGxl PiA8L3JkZjpEZXNjcmlwdGlvbj4gPC9yZGY6UkRGPiA8L3g6eG1wbWV0YT4gPD94cGFja2V0IGVu ZD0iciI/PpCwXwYAAAikSURBVHja7J3RceM2EIZxmStAHRyvAisFJCe9JI8nVSAqKcBWBTpVYLuA jKgKrHvMk+U0EF0FUTpgKnCw9nJGlknJpAgQ5H3fDEe2RYvQgth/FwCBdz/98tujAQAAgLN5b48h ZgAAADifd4+PJKoAAAB18AMmAAAAQFQBAAAQVQAAAEQVAAAAEFUAAABEFQAAAFEFAABAVAEAAABR BQAAQFQBAABaz3tMAFAfP//6+2D/97/+/GODVY7aK7Iv0d6fUmuzLZaBtsLav+4dRlzHZ1lH86Wh Mm18CoMtX5nvudPy7Rqu5759mdtjVHBKYo+Fj3K+sX5Te2ybFHxbTinjpT36BfV6a8t300BbTc6p J71/E1d1rXaLTpy21XaR4oXJVLtGpM62Dr40VKa5bcg+haG0vWz5dlq2pAFx+KJlFkc2tcc6c2bq qAf6fmx/n3kQimivPEVOVYSsp3bzLV49+7LUACS7p9YHAYqI7bX9eWJfh57EIbPbRkX9nPv33M84 xkTLujtRhtTaL7Mv4oqoQoBIhDyyDXW67wQDCl6W6oTHvpyIvd5S7bLI60nQAEQcW6LnilAYTyI2 O5aJquDPtUwX9typJ0G91/oa591H2vU7tefe6rn39uchwvCC1bGeK7VzrPU7wH5+YaISlEEa693h uGFADNQR+xDUWB3X9C1d8ypaiYpYv2lDieBrmX7UYOnaw2WvNUsengrMVFyHKsB3NL1SdZtq4JbZ 7x6rIKpdQTKVRcGRl0UkR853yaagfEXR7Z1Gwz7IK5s4jKLJLP2S47JVBDVSgbgp0+WsIiblHgXk gLNu6yuXwZJ+dqwZ9LZE2caabcW4k0p1O9Y2gf08Qfev42zAFIyFquM/dGKrhiaPPBRlW3tjhocZ 65Wpb5y3atnEfkvzeuLGpX3vxmGX11wDjirBTnBdcZI1WnvJfTcpCPbqstmmbNe3tAcdG5QMf003 Zum6Ffut1f4JFiFTheYbpQjaLOetSQgOwzx3caU5ou8kG9ybJVppAkjAovDVoc0GGkBW7XFZuKzT 74CVBJ567wKiCgGIl2QXu4M/R6GMDdqX25y3LhxdUgQ1bWKmsWOkq7DnqFtfArBd1V4YrWPJti5p jZXI7I6oIqoQEHkTS0JppHkC50rwJwW2aHvgtHFot1ENNpNMuk+2ValuU8dtAhBVqMA3j8JVJZNx zt7qP1+5Hd5ss4F57rpd1RTU0QVcnR4mQFQhHHaY4HliWYDP6dYVMAipI5udtfSgZluSTX/iNqQN I6oA3eCTcTc7tmmiOsQvh4sabSZlowuzfMDUQ1QRVQg0S8txciE4jTxH62KWbdRhx/TZ0Xfr1Xif fDNMtjmn7SKqiCoERN5s2lAaad4424OD64h4/9vRTCY2biZgiUP/r6bP2h0JouB4wLRteuOJ7wUW f4C3ON0oR7iC2KJLy5b3qIULgagz6wqJK/1ut44+f1vz5zDhplz7kIBpijXIVCGcLObOk2iVLVtf y3boZGvfDm5vXCrtWP2Kw5XVdhah22zv0RBEtVzb3XbwuWoyVWhlgxypw41yTll4KsqHnDVp5fcL k9/tmzqKyvsdq9+RZvhiy6Su/Xo92axvOvissIMM9U7b7hCLIKrgF9kztcw+pguP4zOxKbep+iyU saMTC9RvHS9ZeK/74B7jacH1Lj4i1HE+ndg0Igs4n3b6CWGYBlEFKMZVVnMuIqTThjYkKBS2I+9J 9uCyrDPzeixzoD0PkslvmLjSWqIT76faFhJMhahC2CwCFVQRiXWAu7+8K8hgHz1cfnsYYNjrishK l2+EoLaaVaDtEAwTleANztk871/6saGGLMJwah/alC3B3iTyYiPJXnztMESdAJkqkIEGxov9VHXG 798H5zhf5F73pexCXctjM7Iheey6e1DG8hzZbEOTBTJVgJoctXm96MTI4+4lUcvtt1NR8rkfbi02 Y4caQFQB3GVbh8QerpuabiyTJzvGDDyJ1K5Gm0V7nwmAqALURF5Xr4/MS7Lki7YbT7t9RZjmHi4n 1/lQp6g6mmTFYyeAqML3iTrVQ2GNTjwXWpfj7coiEJKtjvZWPWqDzS5ciV8dE9083H+AqAI442sD 2eo3Fe8uLJMn2Wq2kL5rm9UlqgMPGWUdZWXWM6IK0LpsNclxXrFjwcuy41FHsn2x4aXjS200izvL ZlqvIngPDsu6M+etK9xT29KVjKgCtJK8sVVnmZd2EYrD/NwR+62M425zFe86bDY6Uud1iuo5Y+Z9 wyQqRBUTQIvJmwV86eGaoy483qErLu082GxVQ3b/9Cyy40U+zh3/dTbmC4gqgA9R2OY4MdcTliRT Esc+74gZFx6ChMQePd1mrjRanwMVZ5c86P3Tr1DGbFenB1omogrQZlYFWY0rIU9ViOKOzPbMgoTY sc1kqct5xTFvCWB2HnbT2agtqmTuPrqnAVEFcE6S8zenE5asc7/RDHnZ9pnAKnhr474LWAIRsdV1 yQww1ix16tEWpTJ3vQdE+NdsVACIKrSaPUf4SlgdX3qsInFfRlirdoE6RsaJey7LpvU01YAnfqOt pBt2KVmuxy39Zvp6V6JeJVCI9v4XEFWAVpPXBew089KMZKjO9J9TQiGZjz2WKhJJSPu+6tj0xoPN 1iqsyxObbGfBx73aaubRFpn4908FTPKe1qmUdUqWCgK71EAXstW1dW6pefmM4dOEJZfipbuwfFSh FKGYa9Ysk1WyWaoD8zwrVMbcxOmOPYwNVg1M5Dv0XT5nKc8X68411/Z1olny/vUkSJmo3W58CurB /TTWepWAKTGvFxsZaDl7hg3BAVENgsS83sLKx3T8rWZY+4QUYVct29C8fnDf+ffSzGasXZUTzXCu Duy99eh4s/rdlvweInY742E1IL1WlhlfmpcL7mfd+cMms3kV1o3W5eSgTrN7S95feM5QZ4YVm4Lm fwEGAMnxhvP4i6fSAAAAAElFTkSuQmCC ------=_NextPart_000_00B1_01DCD106.238303F0--